Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.
Brian I. Rini
Consultant or Advisory Role - Argos Therapeutics; AVEO; Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer
Viktor Gruenwald
Consultant or Advisory Role - AVEO; AVEO; Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche
Honoraria - Bayer; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer; Roche
Mayer N. Fishman
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Bohuslav Melichar
No relevant relationships to disclose
Takeshi Ueda
Honoraria - Pfizer
A. H. Bair
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Ying Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Paul W. Bycott
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Dmitri Pavlov
Employment or Leadership Position - Pfizer; Pfizer
Stock Ownership - Pfizer; Pfizer
Sinil Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Eric Jonasch
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer